An update from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals Ltd. announced a live webinar to discuss its latest Phase II clinical trial data, new pre-clinical findings, and ongoing operational activities, including a Phase 3 Clinical Trial in Indonesia. The event aims to highlight significant progress in Recce’s anti-infective programs and will feature expert speakers from the company and its research partners, providing valuable insights into its strategic advancements.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of a new class of synthetic anti-infectives. The company is engaged in advancing its anti-infective programs with a market focus on clinical trials and research collaborations.
YTD Price Performance: -10.42%
Average Trading Volume: 116,515
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$99.7M
See more data about RCE stock on TipRanks’ Stock Analysis page.